Takeda drops $300M cash to kick off $1B RNAi alliance with Arrowhead, shooting for first-in-class rare disease drug
Twelve years ago, Takeda became the first major Asian pharma company to buy into Alnylam’s pioneering RNAi platform with a landmark $1 billion alliance. Two FDA approvals and a slew of new deals for the field later, the Japanese drugmaker is making a new $1.04 billion bet on a rare disease program from a J&J-partnered RNAi player.
Arrowhead is grabbing $300 million of that upfront in exchange for co-development and co-commercialization rights of ARO-AAT, which is designed to knock down the production of mutant alpha-1 antitrypsin proteins in patients with AAT-associated liver disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.